💊#FDA Approval Update | #Komzifti (#ziftomenib) for relapsed or refractory #AML with #NPM1 mutation in adults
⚙️Blocks #menin-KMT2A interaction, disrupting leukemogenic gene expression
🌟MedChemExpress provides ziftomenib for research use.
#AcuteMyeloidLeukemia #Leukemia

Kura Oncology secures approval for leukemia drug, its first The FDA approved a drug made by Kura Oncology to treat patients with a certain type of genetically altered leukemia.

La #FDA a autorisé un médicament #Komzifti 💊 fabriqué par #KuraOncology pour traiter les patients atteints de #Leucémie myéloïde aiguë ( #LMA 🩸) R/R, causée par une mutation du gène appelé #NPM1, à l’origine d’environ 30 % de tous les cas de #LAM 🩸

www.statnews.com/2025/11/13/k...

Kura scores FDA okay for rival to Syndax's leukaemia drug Kura has claimed FDA approval for oral menin inhibitor Komzifti for acute myeloid leukaemia, setting up a battle with Syndax's rival Revuforj.

#KuraOncology has claimed FDA approval for oral menin inhibitor #Komzifti for a form of acute myeloid leukaemia (#AML), making it the first direct competitor to #Syndax's Revuforj, which launched in the US last year.